This study evaluated the efficacy and safety of canagliflozin , a sodium glucose co-transporter @ inhibitor , in patients with type @ diabetes mellitus ( T@DM ) and within a subset of Stage @ chronic kidney disease ( CKD ; estimated glomerular filtration rate -LSB- eGFR -RSB- @ and < @ ml/min/@ @ m ( @ ) ) .